Senator Drops Deadly Charge Against Fauci

In the struggle over how to interpret the COVID-19 years, Senator Cynthia Lummis’s accusations against Anthony Fauci crystallize a larger fight: whether key public‑health leaders merely got hard calls wrong or actively blocked life‑saving early treatments and then misled Congress about it.

Key Points

Sen. Cynthia Lummis has publicly alleged that Dr. Anthony Fauci lied to Congress and the American people about COVID-19 treatments and bears responsibility for “the overwhelming number of deaths” in the U.S. because he opposed ivermectin.
Her claims build on a broader Republican narrative, buttressed by newly declassified intelligence‑community documents and multiple hearings, that Fauci misled lawmakers on research funding, gain-of-function work, and pandemic decision‑making.
Fauci has consistently dismissed ivermectin and hydroxychloroquine as unproven and potentially harmful for COVID‑19, a position aligned with FDA and NIH guidance and reinforced in his sworn testimony and diary excerpts.
Congressional investigations and outside scientific bodies are divided: GOP‑led committees and some experts assert Fauci was “untruthful,” while other official reviews and large groups of scientists defend his integrity and decisions.
The Lummis–Fauci clash illustrates how a technical dispute over drug efficacy became a proxy for deeper battles over trust in institutions, emergency powers, and the politicization of “following the science.”

Sen. Lummis’s Charge: Linking Fauci, Ivermectin, and U.S. COVID Deaths

Senator Cynthia Lummis, a Republican from Wyoming, has moved beyond the general criticism many conservatives level at Anthony Fauci and made a stark, causal accusation: that he lied and that his opposition to ivermectin cost American lives. In an interview with The Gateway Pundit, she stated that Fauci “has certainly lied to the American people and to the Congress” and went further, arguing, “He’s responsible for the overwhelming number of deaths that occurred in this country that did not occur in other countries because they were using ivermectin.” That framing does two things at once. It casts ivermectin not as a marginal or speculative therapy but as a “successful and inexpensive and readily available treatment,” and it treats U.S. mortality as the foreseeable consequence of a deliberate decision by Fauci to oppose it.

Lummis’s comments do not arise in a vacuum. By the time she spoke, Republican senators like Ron Johnson had spent years insisting that randomized trials showed substantial benefit from ivermectin, accusing federal agencies of “overtly discouraging” cheap early treatments in favor of drugs such as remdesivir. Johnson and others pointed to foreign countries where ivermectin was used more widely and contrasted their outcomes with the U.S., though those cross‑national comparisons involve many confounding factors—vaccination timing, age structures, and reporting practices among them. Lummis effectively distills these threads into a single moral claim: if America had embraced ivermectin, “the overwhelming number” of COVID‑19 deaths here would have been avoided.

What Fauci Actually Said About Ivermectin and Early Therapies

To understand the charge that Fauci lied, it matters to be precise about his public record. In August 2021, as poison control centers reported spikes in calls linked to veterinary formulations of ivermectin, Fauci told CNN, “Don’t do it; there’s no evidence that it works,” warning that misuse was more likely to cause harm than benefit. That statement aligned with concurrent FDA and NIH guidance, which held that, at that point, available clinical trials had not shown ivermectin to be safe and effective for preventing or treating COVID‑19. Fauci’s general position, reiterated in later testimony, was that therapies should be adopted when high‑quality, controlled studies demonstrate benefit, not on the basis of anecdote or small, methodologically weak trials.

Critics seize on two aspects of this posture. First, they argue that by the time Fauci was saying “no evidence,” a number of randomized controlled trials and meta‑analyses suggested ivermectin had non‑trivial efficacy—claims often highlighted at Senate hearings and in conservative media. Second, they contend that federal messaging did not simply await better data; it actively stigmatized physicians who prescribed ivermectin off‑label, contributing to hospital sanctions and professional risk. In their telling, statements like “don’t do it” functioned not as cautious scientific caveats but as institutional commands that closed off early‑treatment pathways, leaving patients with fewer options.

Fauci’s defenders counter that the bar for changing national treatment standards must remain high in a fast‑moving pandemic, and that most ivermectin studies were underpowered, poorly controlled, or contradicted by later, more rigorous trials. They argue that the insistence on “no evidence” was shorthand for “no high‑quality evidence,” and that when data changed, guidance did as well—for example, as large steroid trials clarified benefit in severe disease. That epistemic dispute—what counts as sufficient evidence in crisis—sits at the heart of the Lummis accusations.

Congressional Republicans’ Wider Case: Lying, Cover‑Ups, and a Presidential Pardon

Lummis’s statements are also nested within a much broader campaign to portray Fauci as deceptive and self‑protective. House and Senate Republicans have repeatedly accused him of lying about gain-of-function research funding in Wuhan, manipulating intelligence assessments on COVID‑19 origins, and suppressing dissenting scientific views. Newly declassified documents released by Director of National Intelligence Tulsi Gabbard, for example, were described as showing Fauci “worked with politicized career leadership in the Intelligence Community to suppress the truth about his actions, the virus’ lab-leak origins, and his role in directing U.S. funding for this dangerous research.” Those records, according to Gabbard’s office, also suggest Fauci misled Congress in 2024 by denying under oath his involvement in discussions with intelligence officials about viral research.

Alongside these disclosures, Republican committee chairs have used public hearings to press the narrative. Oversight materials from a select subcommittee summarize their view bluntly: members questioned Fauci about “his clearly misleading statements before Congress and the public, and his gross mismanagement” of NIAID. Individual lawmakers amplified the charge. Representative Nancy Mace asserted that Fauci “looked Congress in the eye and lied under oath” about funding research tied to the pandemic, pointing to admissions from NIH deputies as proof. Representative James Comer called the situation “the biggest cover-up in American history,” arguing that decisions “based solely on what Dr. Fauci was saying” caused sweeping pain.

The political stakes of this narrative were heightened by President Biden’s decision, at the close of his term, to grant Fauci a broad pardon covering potential federal offenses linked to his pandemic role. For critics like Lummis, the pardon functions as a kind of circumstantial confirmation: if there were nothing to hide, why shield Fauci preemptively? For supporters, it reads as a prophylactic against what they see as retaliatory criminalization of policy debates. Either way, the pardon ensures that many of the allegations—lying under oath, misuse of funds—will be litigated primarily in congressional and public forums rather than in court.

Countervailing Assessments: Committees and Scientists Who Clear Fauci

The accusation that Fauci “lied” is not uncontested in institutional records. In a detailed report from a House hearing, committee leadership concluded, after reviewing hundreds of thousands of pages of documents and interviewing witnesses, that “Dr. Fauci did not fund research through the EcoHealth Alliance grant that caused the COVID–19 pandemic” and “did not lie about gain-of-function research in Wuhan, China” or orchestrate a campaign to suppress the lab-leak theory. That formal finding directly rebuts central elements of the Republican case on origins and research funding, though it does not address ivermectin specifically.

Outside Congress, large groups of scientists have intervened. In response to escalating attacks, more than 150 infectious‑disease experts and allied scientists signed a public letter stating that “no credible evidence has been produced to support these absurd charges” against Fauci and urging lawmakers to end what they described as “witch-hunts.” Separately, dozens of Nobel laureates endorsed a letter defending evidence‑based public‑health leadership and warning about the consequences of politicizing technical decision‑making. These interventions do not claim perfection in every pandemic call; rather, they insist that labelling Fauci a liar or murderer based on contested interpretations of complex science crosses a line from accountability into opportunistic scapegoating.

Media fact‑checking has generally tracked this split. Outlets such as The Washington Post have examined claims that NIH “admitted” to gain-of-function funding and concluded that the relevant letters do not support the charge, noting that NIH officials maintain the funded work did not meet their definition of gain-of-function. Analytical pieces in venues like The Conversation and Science frame the hearings as examples of conspiracy narratives becoming political weapons—suggesting that while legitimate oversight is essential, repeated, unproven assertions of cover‑ups can erode public trust without improving future pandemic preparedness.

Ivermectin as Proxy: Evidence Thresholds and Epistemic Conflict

When Lummis says “virologists worldwide knew that ivermectin was a successful treatment and inexpensive,” she is not making a nuanced claim about marginal benefit or conditional efficacy; she is asserting that a clear, consensus truth existed and that Fauci chose to resist it. The difficulty is that the published record does not show the kind of unified global virology consensus those words imply. Instead, it shows a contested literature: some smaller or early studies indicating possible benefit, others finding none, and higher‑quality trials over time trending toward neutral or modest effects insufficient to change standard of care.

In that context, labeling Fauci’s “no evidence” line a lie depends on how one defines evidence. If any positive trial counts, then his statement was too categorical and arguably wrong. If “evidence” in national guidance means robust, reproducible, bias‑resistant findings, his caution was consistent with mainstream practice. Both sides appeal to science, but they operate with different risk tolerances: early‑treatment advocates view off‑label use of a long‑approved drug as a low‑cost bet, while regulators prioritize avoiding widespread adoption of therapies whose benefits are uncertain and whose harms, particularly at mis‑dosed levels, are real.

That divergence is not new in medicine, but COVID‑19 amplified it, because every delay or restriction could be portrayed as costing lives. For many Americans, especially those who lost family during periods when hospitals seemed to offer little beyond oxygen, ventilation, and eventually remdesivir, the idea that inexpensive pills might have helped—and were blocked for political or financial reasons—has enduring emotional power. Lummis’s claim that Fauci is “responsible” for the overwhelming number of deaths draws strength from that grief, even as the causal chain she sketches is far more complex than a single drug and a single advisor.

What This Fight Reveals About Trust, Expertise, and Future Crises

Whether one accepts Lummis’s indictment or sides with the scientists defending Fauci, her remarks illuminate a structural problem that will outlast this particular controversy: the fragility of trust in expert institutions during catastrophe. When public‑health leaders say “no evidence” and later data revise the picture, accusations of lying find an eager audience. When elected officials translate technical disputes into charges of criminal deceit, the boundary between oversight and weaponization blurs.

The ivermectin saga, and the broader campaign against Fauci, should prompt two sober reflections. First, emergency guidance must be both transparent about uncertainty and agile in response to emerging results; categorical dismissals that sound absolute can age badly, even when grounded in the best available data at the time. Second, accountability mechanisms need to distinguish between bad faith and bad bets. If every contested call is retroactively framed as deliberate murder or cover‑up, fewer qualified experts will be willing to serve in future crises, and the country will be left more vulnerable when it most needs calm, technically grounded leadership.